Explore the words cloud of the CARDIACSENSE project. It provides you a very rough idea of what is the project "CARDIACSENSE" about.
The following table provides information about the project.
|Coordinator Country||Israel [IL]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2018-12-01 to 2019-03-31|
Take a look of project's partnership.
Atrial fibrillation (AF) is the most common heart arrhythmia in adults and a major risk factor for ischaemic stroke (increased by 500%), costing globally around €500Bn/year. On the other hand, Hypertension (HTN) is a condition, mostly encountered in patients suffering from AF, although only half of these individuals have this condition under control, and only 20% are unaware that they have HTN. Besides the health risks associated with these conditions, there is a lack of non-obtrusive, non-inflating, non-invasive, small, precise, easy-to-use devices for continuous monitoring of vital signs, including AF and blood pressure. Cardiac Sense Ltd is an Israeli start-up established in 2009, with a vision of developing innovative non-invasive technology for monitoring vital signs. We are developing CardiacSense (TRL6), a clinically-proven medical solution that reliably delivers non-invasive and non-inflating heart arrhythmia and blood pressure monitoring, 23/365 for as long as needed. It mainly consists of a wearable (a watch), highly sensitive, error-free (introducing an artefact sensor), real-time measuring device, that is non-invasive (no surgery needed), easy to use (no training needed) and allows for a great connectivity (providing easy data storage and sharing). Our solution is based on optical PPG sensor technology to monitor heart AF and BP. In addition, we are the first company to develop a unique artefact sensor that detects finger and wrist movements that affect the PPG signal by increasing false positive results. Our solution thus has a medical grade accuracy level of pulse measurement. Through this project we aim to finalize its development and launch it to the market, with a potential to save around €800M to EU healthcare and save up to 5,000 lives yearly, and to boost our company's growth to €7.5M revenues, and 20 new jobs by 2025.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CARDIACSENSE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CARDIACSENSE" are provided by the European Opendata Portal: CORDIS opendata.